Compare EBON & OSRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EBON | OSRH |
|---|---|---|
| Founded | 2010 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.0M | 17.9M |
| IPO Year | 2020 | 2022 |
| Metric | EBON | OSRH |
|---|---|---|
| Price | $2.01 | $0.48 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.4K | ★ 17.3M |
| Earning Date | 04-24-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,905,805.00 |
| Revenue This Year | N/A | $9.30 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.61 | $0.25 |
| 52 Week High | $5.90 | $1.24 |
| Indicator | EBON | OSRH |
|---|---|---|
| Relative Strength Index (RSI) | 47.70 | 76.30 |
| Support Level | $1.73 | $0.40 |
| Resistance Level | $2.76 | $0.90 |
| Average True Range (ATR) | 0.19 | 0.09 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 54.90 | 96.39 |
Ebang International Holdings Inc is engaged in blockchain technology and fintech, with activities also extending to the solar industry, supported by its application-specific integrated circuit (ASIC) chip designs. The Company's business mainly includes the sale of bitcoin mining machines and related accessories, telecommunication products, solar and battery storage products, cryptocurrency exchange services, cross-border payment and foreign exchange services, SaaS data visualization and analytics solutions, and rental services. It generates the majority of its revenue from cross-border payment and foreign exchange services, with its operations mainly in mainland China and Australia, which contribute the maximum revenue.
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea. The company's pipeline products include: Vaximm, Darnatein, Woori IO, and RMC.